Effect of Dietary Macronutrient Composition
Primary Purpose
Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Obesity
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Low-fat diet
Low-carbohydrate diet
Sponsored by
About this trial
This is an interventional basic science trial for Metabolic Syndrome focused on measuring Metabolic syndrome, Non-alcoholic fatty liver disease, Obesity Metabolism, Stable isotopes, Dietary weight loss
Eligibility Criteria
Inclusion Criteria:
- Elevated serum ALT or metabolic syndrome
- African American or Hispanic
- Nondiabetic
- Men or women
- Smokers and nonsmokers
- Pre- and post-menopausal (+/- HRT)
- Stable body weight
- Age 20-65 years
- BMI between 25-45 kg/m2
Exclusion Criteria:
- Diabetes or Pregnancy
- Ethanol intake: males > 140 g/week, females > 70 g/week
- Chronic hepatitis B or chronic hepatitis C
- Hemochromatosis or Wilson's Disease
- Autoimmune hepatitis or primary biliary cirrhosis
Sites / Locations
- Center for Human Nutrition
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Hispanic subjects
African American subjects
Arm Description
Subjects will identify as Hispanic ethnicity.
Subjects will self-identify as African American in origin.
Outcomes
Primary Outcome Measures
de novo lipogenesis
In vivo measurement is made of liver fatty acid synthesis using stable isotope administration and analysis of plasma samples by GS/MS
Secondary Outcome Measures
Dietary fatty acid clearance to liver
Using a dietary stable isotope we will quantitate fat absorption and recycling of fat through the liver.
Adipose fatty acid flux
A stable isotope is infused and the rate of adipose fatty acid release is calculated after analyzing blood samples.
Full Information
NCT ID
NCT01371396
First Posted
June 7, 2011
Last Updated
February 4, 2019
Sponsor
University of Texas Southwestern Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT01371396
Brief Title
Effect of Dietary Macronutrient Composition
Official Title
Effect of Dietary Macronutrient Composition on Liver Substrate Metabolism
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
September 1, 2007 (Actual)
Primary Completion Date
December 31, 2013 (Actual)
Study Completion Date
December 31, 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Texas Southwestern Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to understand why Hispanics who are overweight have a higher incidence of fatty liver disease.
Detailed Description
Obesity is a major factor driving the increased prevalence of hepatic steatosis in the US. However, little is known regarding the relationship between dietary intake and hepatic fat deposition or about the factors that promote loss of hepatic steatosis. Here, the investigators will determine how differences in dietary composition affect the development and regression of fatty liver. The investigators hypothesize that Hispanic subjects with metabolic syndrome will have higher liver fat synthesis rates compared to African American subjects.
Using detailed in vivo, serial measurements of fuel metabolism (GC/MS and NMR) fatty acid metabolism will be measured in the liver and periphery. This will be the first study in which these two methodologies are used together to assess both glucose and fatty acid metabolism in the same subjects. Subjects will be tested before and after a dietary weight-loss intervention producing 6% body weight loss over 5 months.
The specific aims are as follows:
AIM 1: Determine the contribution of peripheral and dietary fat to liver-TG in Hispanics and African Americans with metabolic syndrome.
Hypothesis: De novo lipogenesis will contribute to liver-TG in greater quantities compared to African Americans.
AIM 2: Determine the effects of low-CHO and low-fat diets on liver fat regression.
Hypothesis: Compared to a low-fat diet, a low-CHO diet will markedly decrease markers of inflammation coincident with greater improvements in insulin sensitivity as assessed by an intravenous glucose tolerance test.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Obesity
Keywords
Metabolic syndrome, Non-alcoholic fatty liver disease, Obesity Metabolism, Stable isotopes, Dietary weight loss
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Hispanic subjects
Arm Type
Other
Arm Description
Subjects will identify as Hispanic ethnicity.
Arm Title
African American subjects
Arm Type
Other
Arm Description
Subjects will self-identify as African American in origin.
Intervention Type
Other
Intervention Name(s)
Low-fat diet
Intervention Description
The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.
Intervention Type
Other
Intervention Name(s)
Low-carbohydrate diet
Intervention Description
The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.
Primary Outcome Measure Information:
Title
de novo lipogenesis
Description
In vivo measurement is made of liver fatty acid synthesis using stable isotope administration and analysis of plasma samples by GS/MS
Time Frame
Change from Baseline in fatty acid synthesis at 5 months
Secondary Outcome Measure Information:
Title
Dietary fatty acid clearance to liver
Description
Using a dietary stable isotope we will quantitate fat absorption and recycling of fat through the liver.
Time Frame
Change from Baseline in dietary fat clearance at 5 months
Title
Adipose fatty acid flux
Description
A stable isotope is infused and the rate of adipose fatty acid release is calculated after analyzing blood samples.
Time Frame
Change from Baseline in adipose fat flux at 5 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Elevated serum ALT or metabolic syndrome
African American or Hispanic
Nondiabetic
Men or women
Smokers and nonsmokers
Pre- and post-menopausal (+/- HRT)
Stable body weight
Age 20-65 years
BMI between 25-45 kg/m2
Exclusion Criteria:
Diabetes or Pregnancy
Ethanol intake: males > 140 g/week, females > 70 g/week
Chronic hepatitis B or chronic hepatitis C
Hemochromatosis or Wilson's Disease
Autoimmune hepatitis or primary biliary cirrhosis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elizabeth J Parks, PhD
Organizational Affiliation
UTSW Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for Human Nutrition
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390-9052
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
22045665
Citation
Shetty S, Ramos-Roman MA, Cho YR, Brown J, Plutzky J, Muise ES, Horton JD, Scherer PE, Parks EJ. Enhanced fatty acid flux triggered by adiponectin overexpression. Endocrinology. 2012 Jan;153(1):113-22. doi: 10.1210/en.2011-1339. Epub 2011 Nov 1.
Results Reference
result
PubMed Identifier
21820684
Citation
Ramos-Roman MA, Sweetman L, Valdez MJ, Parks EJ. Postprandial changes in plasma acylcarnitine concentrations as markers of fatty acid flux in overweight and obesity. Metabolism. 2012 Feb;61(2):202-12. doi: 10.1016/j.metabol.2011.06.008. Epub 2011 Aug 5.
Results Reference
result
PubMed Identifier
22152305
Citation
Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011 Dec 7;14(6):804-10. doi: 10.1016/j.cmet.2011.11.004.
Results Reference
result
PubMed Identifier
27035816
Citation
Satapati S, Kucejova B, Duarte JA, Fletcher JA, Reynolds L, Sunny NE, He T, Nair LA, Livingston KA, Fu X, Merritt ME, Sherry AD, Malloy CR, Shelton JM, Lambert J, Parks EJ, Corbin I, Magnuson MA, Browning JD, Burgess SC. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J Clin Invest. 2016 Apr 1;126(4):1605. doi: 10.1172/JCI86695. Epub 2016 Apr 1. No abstract available.
Results Reference
result
PubMed Identifier
25527748
Citation
Lee JJ, Lambert JE, Hovhannisyan Y, Ramos-Roman MA, Trombold JR, Wagner DA, Parks EJ. Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. Am J Clin Nutr. 2015 Jan;101(1):34-43. doi: 10.3945/ajcn.114.092262. Epub 2014 Nov 19.
Results Reference
result
PubMed Identifier
27152153
Citation
Lambert JE, Parks EJ. Getting the label in: practical research strategies for tracing dietary fat. Int J Obes Suppl. 2012 Dec;2(Suppl 2):S43-50. doi: 10.1038/ijosup.2012.22. Epub 2012 Dec 11.
Results Reference
result
PubMed Identifier
22723441
Citation
Ramos-Roman MA, Lapidot SA, Phair RD, Parks EJ. Insulin activation of plasma nonesterified fatty acid uptake in metabolic syndrome. Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1799-808. doi: 10.1161/ATVBAHA.112.250019. Epub 2012 Jun 21.
Results Reference
derived
Learn more about this trial
Effect of Dietary Macronutrient Composition
We'll reach out to this number within 24 hrs